全文获取类型
收费全文 | 620篇 |
免费 | 25篇 |
国内免费 | 19篇 |
专业分类
儿科学 | 24篇 |
基础医学 | 33篇 |
口腔科学 | 35篇 |
临床医学 | 47篇 |
内科学 | 136篇 |
皮肤病学 | 4篇 |
神经病学 | 15篇 |
特种医学 | 166篇 |
外科学 | 53篇 |
综合类 | 17篇 |
预防医学 | 50篇 |
眼科学 | 2篇 |
药学 | 49篇 |
2篇 | |
肿瘤学 | 31篇 |
出版年
2023年 | 1篇 |
2021年 | 1篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2018年 | 5篇 |
2017年 | 2篇 |
2016年 | 2篇 |
2015年 | 4篇 |
2014年 | 5篇 |
2013年 | 9篇 |
2012年 | 15篇 |
2011年 | 10篇 |
2010年 | 7篇 |
2009年 | 13篇 |
2008年 | 9篇 |
2007年 | 22篇 |
2006年 | 16篇 |
2005年 | 6篇 |
2004年 | 8篇 |
2003年 | 5篇 |
2002年 | 14篇 |
2001年 | 4篇 |
2000年 | 12篇 |
1999年 | 16篇 |
1998年 | 29篇 |
1997年 | 27篇 |
1996年 | 32篇 |
1995年 | 29篇 |
1994年 | 23篇 |
1993年 | 25篇 |
1992年 | 9篇 |
1991年 | 12篇 |
1990年 | 17篇 |
1989年 | 43篇 |
1988年 | 27篇 |
1987年 | 35篇 |
1986年 | 21篇 |
1985年 | 34篇 |
1984年 | 19篇 |
1983年 | 20篇 |
1982年 | 10篇 |
1981年 | 8篇 |
1980年 | 13篇 |
1979年 | 11篇 |
1978年 | 9篇 |
1977年 | 13篇 |
1976年 | 7篇 |
1973年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有664条查询结果,搜索用时 78 毫秒
51.
52.
53.
关节部位Ⅲ度烧伤削痂植皮与切痂植皮的效果比较 总被引:3,自引:0,他引:3
目的:Ⅲ度烧伤创面的处理临床上仍然以切痂植皮术治疗为主,由于切痂时切除了并未损伤的皮下脂肪组织,使其愈后外观变化明显。实验拟观察关节部位Ⅲ度烧伤削痂后于脂肪层移植大张自体中厚皮的疗效,并与切痂植皮进行比较。方法:①于2001-01/2007-06南昌大学第一附属医院烧伤科收治的关节Ⅲ度烧伤患者中抽取39例(45个关节)作为削痂组,同时抽取45例(共60个关节)作为切痂组。所有患者对治疗及实验方案均知情同意,且得到医院伦理道德委员会批准。②削痂组削痂植皮,保留正常皮下脂肪等组织。切痂组切痂植皮,切痂平面包括全层皮肤和皮下脂肪组织一并切除直至深筋膜层。削痂或切痂后植大张自体中厚皮。③创面修复后4 ̄6周观察两组患者的关节外观和关节活动功能;比较两组患者术后2周的植皮成活率和创面修复时间。结果:两组患者均进入结果分析。①两组患者烧伤关节创面修复后与对称的正常关节比较,削痂组外观变化不明显,周径缩小3.6%(P>0.05),功能好,关节活动度减少5.3%(P>0.05);切痂组外观变化明显,周径缩小23.4%(P<0.05),功能较差,关节活动度减少21.9%(P<0.05)。②两组患者术后2周植皮成活率和创面修复时间差异均无显著性意义(P>0.05)。结论:脂肪层移植大张自体中厚皮于Ⅲ度烧伤削痂后关节部位,能够维护肢体的美观,保护关节功能,疗效优于切痂植皮。 相似文献
54.
预防治疗2型糖尿病药物分子作用靶点的相关研究与进展 总被引:1,自引:0,他引:1
目的:综合分析2型糖尿病新药研究的分子靶点。资料来源:应用计算机检索Springer1990-01/2005-02和Pubmed2000-01/2005-08有关预防和治疗2型糖尿病药物的文献,检索词“diabetes,drug,target”,并限定文献语言种类为English。资料选择:对检索到的有关预防和治疗2型糖尿病药物的相关信息进行整理,筛选针对性强、影响因子较大、最近几年发表的论文。资料提炼:共检索到相关文献49篇,其中15篇符合要求,排除34篇。排除的文章中6篇是关于2型糖尿病的病理生理及生化方面的基础研究,其余为2型糖尿病预防和治疗效果方面的文献。资料综合:综合文献资料发现,以往研制的治疗糖尿病的药物或者因缺乏明确的分子靶点,或者因对疾病本身的病理反应不清楚,因而存在各种弊端。有关预防和治疗2型糖尿病和代谢综合征的分子靶点为抗糖尿病药物的研发展示了光明的前景,涉及的药物包括经典受体的小分子调节剂、酶作用靶点、蛋白质制剂和反义寡核苷酸等。结论:根据2型糖尿病和代谢综合征特异的病理反应机制作为筛选药物的分子基础是未来抗糖尿病药物研发的主攻方向。 相似文献
55.
OBJECTIVES: To analyze managed care organizations' (MCOs') use of behavioral health quality management activities using nationally representative survey data. MATERIALS AND METHODS: The primary data source is the Brandeis Survey on Alcohol, Drug Abuse, and Mental Health Services in MCOs. Using a sampling strategy designed for national estimates, we surveyed 434 MCOs in 60 market areas (response rate = 92%) regarding their commercial products' behavioral health services in 1999. Of these, 417 MCOs reported clinically oriented information for 752 products. We investigated the use of four behavioral health quality management activities: patient satisfaction surveys, clinical outcomes assessment, performance indicators, and practice guidelines. chi tests and logistic regression were used to determine effects of product type (HMO, PPO, point-of-service) and behavioral health contracting arrangement (specialty contract, comprehensive contract including general medical and behavioral health, internal provision). RESULTS: Three-quarters of products used patient satisfaction surveys (70.1%), performance indicators (72.7%), and practice guidelines (73.8%) for behavioral health. Under half (48.9%) assessed clinical outcomes. HMO products were most likely, and PPOs least likely, to conduct activities. Quality activities were significantly more common among specialty-contract products. Logistic regression showed significant negative effects on quality activity use for PPO and POS products compared with HMOs. For clinical outcomes, specialty- and comprehensive-contract arrangements had significant positive effects. There were interactions between product type and contract arrangement. CONCLUSIONS: Most commercial managed care products use patient satisfaction surveys, performance indicators, and practice guidelines for behavioral health, whereas clinical outcomes assessment is less common. Product type and contracting arrangements significantly affect use of these activities. 相似文献
56.
Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates.
下载免费PDF全文
![点击此处可从《The Journal of clinical investigation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
A P Gillio C Gasparetto J Laver M Abboud M A Bonilla M B Garnick R J O''''Reilly 《The Journal of clinical investigation》1990,85(5):1560-1565
Interleukin-3 (IL-3) is a hematopoietic growth factor that supports the growth of early hematopoietic progenitors in vitro. In vivo administration of recombinant human interleukin-3 (rhIL-3) to normal primates results in a modest and delayed leukocytosis secondary to increases in neutrophils, basophils, and eosinophils. We postulated that the effects of rhIL-3 might be more pronounced in hematologically stressed primates, and therefore administered rhIL-3 to primates after intensive myelosuppressive therapy. Primates received either cyclophosphamide (CPM) at 60 mg/kg or 5-fluorouracil (5-FU) at 75 mg/kg i.v. on two consecutive days. Subsequently, rhIL-3 was administered intravenously or subcutaneously at 20 micrograms/kg per d for 14 d. Compared to controls, all rhIL-3 treated primates experienced higher absolute neutrophil count (ANC) nadirs and dramatic decreases in the period of severe neutropenia (ANC less than 500) after myelosuppressive therapy. RhIL-3 administration resulted in a significant basophilia and eosinophilia, which resolved after discontinuation of the drug. RhIL-3 did not enhance erythroid recovery. Platelet recovery was earlier in rhIL-3-treated animals. However, variations in the platelet recovery observed in control animals, precluded accurate estimation of this effect or its significance. Our results indicate that the administration of rhIL-3 following intensive myelosuppressive therapy dramatically enhances myeloid recovery and ablates the predicted period of prolonged severe neutropenia. 相似文献
57.
BACKGROUND: Mental health and substance use conditions are under-recognized and under-treated. Private health plans may be able to affect the extent of screening and, thus, identification of enrollees who need treatment. OBJECTIVES: The goals of this study were to determine strategies used by health plans to identify mental health and substance use conditions; and describe the characteristics of health plans associated with use of these strategies. METHODS: In 2003, we conducted a nationally representative survey of private health plans regarding behavioral health services. A total of 368 health plans (83% response rate) provided information about their managed care products: health maintenance organization (HMO), point-of-service (POS), or preferred provider organization (PPO) products (812 in total). MEASURES: We asked whether plans verify primary care providers' screening for mental health or substance use conditions, screen outside of primary care, and distribute practice guidelines. We characterized each product in terms of "carve-out" to a specialty behavioral health vendor, tax status, and region and market area population. RESULTS: Thirty-four percent of products verify primary care providers' screening for mental health, but only 8% verify alcohol or drug screening. Outside of primary care, 31% conduct screening through the mail, phone, or internet. Depression guidelines are distributed to primary care providers by 78% of managed care products: alcohol or drug guidelines are distributed by 33%. In multivariate analyses, specialty contracting was positively associated, and PPO product type was negatively associated with these strategies. CONCLUSIONS: Most health plans use multiple strategies to improve identification of behavioral health conditions, but use of such strategies was greater for mental health than for substance use conditions. 相似文献
58.
Thomas CP Garnick DW Horgan CM McCorry F Gmyrek A Chalk M Gastfriend DR Rinaldo SG Albright J Capoccia VA Harris AH Harwood HJ Greenberg P Mark TL Un H Oros M Stringer M Thatcher J 《Journal of substance abuse treatment》2011,40(1):35-43
Performance measures have the potential to drive high-quality health care. However, technical and policy challenges exist in developing and implementing measures to assess substance use disorder (SUD) pharmacotherapy. Of critical importance in advancing performance measures for use of SUD pharmacotherapy is the recognition that different measurement approaches may be needed in the public and private sectors and will be determined by the availability of different data collection and monitoring systems. In 2009, the Washington Circle convened a panel of nationally recognized insurers, purchasers, providers, policy makers, and researchers to address this topic. The charge of the panel was to identify opportunities and challenges in advancing use of SUD pharmacotherapy performance measures across a range of systems. This article summarizes those findings by identifying a number of critical themes related to advancing SUD pharmacotherapy performance measures, highlighting examples from the field, and recommending actions for policy makers. 相似文献
59.
Garnick MB 《JAMA : the journal of the American Medical Association》2012,307(13):1372; author reply 1372-1372; author reply 1374
60.
BACKGROUND Screening for substance abuse and mental health in primary care can improve detection. One way to advance screening is for
health plans to require it.
OBJECTIVES We developed national estimates of the prevalence and type of mental and substance-use condition screening health plans require
of primary care practitioners.
DESIGN In 1999 (N = 434, response rate = 92%) and 2003 (N = 368, response rate = 83%), we conducted a nationally representative health plan survey regarding alcohol, drug, and mental
health services, including screening requirements.
PARTICIPANTS Health plans reported on screening requirements of their top three private insurance products. Products were categorized by
type (HMO, POS, or PPO), behavioral health contracting arrangements, tax status, market area population, and region.
MEASUREMENTS We asked whether primary care practitioners are required to use a general health screening questionnaire (including mental
health, alcohol, or drugs items) and/or a screening questionnaire focused on mental health, alcohol, or drug problems.
RESULTS By 2003, 34% of products had any behavioral health screening requirements. Although there was no increase from 1999 to 2003
in requirements for any kind of behavioral health screening, requirements for using a standard screening instrument declined
for mental health but increased for alcohol and drug screening. PPOs showed the largest increase in prevalence of behavioral
health screening requirements. Products contracting with managed behavioral health organizations were more likely to require
screening.
CONCLUSIONS Most products do not require behavioral health screening in primary care. More screening could help to improve identification
of behavioral health conditions, a first step towards effective treatment. 相似文献